Using ultrasound to improve diagnosis of nerve disorders like GBS and CIDP

A Comparative Study of Peripheral Nerve Ultrasound Findings in Immune Mediated Peripheral Nerve Disorders; a Hospital-based Study

This study is testing if using ultrasound can help doctors better diagnose nerve disorders like Guillain-Barré Syndrome and CIDP by comparing ultrasound results with other nerve tests.

Quick facts

• Study type: Observational
• Enrollment: 90 (estimated)
• Ages: 18 Years to 75 Years
• Sex: All
• Sponsor: Assiut University (Academic / other)
• Locations: 1 site (Asyut)
• Trial ID: NCT06615622 on ClinicalTrials.gov

What this trial studies

This study investigates the use of neuromuscular ultrasound (NMUS) to detect nerve alterations in patients with Guillain-Barré Syndrome (GBS) and Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP). By performing serial nerve ultrasounds and nerve conduction studies (NCS), the researchers aim to determine if ultrasound findings correlate with electrodiagnostic results, which could aid in early diagnosis and intervention. The study focuses on differentiating between axonal and demyelinating subtypes of these conditions, potentially improving patient outcomes through better understanding and management of the diseases.

Who should consider this trial

Good fit: Ideal candidates include adults aged 18 to 75 recently diagnosed with GBS or those with a relapsing or progressive course of CIDP.

Not a fit: Patients with metabolic disorders, malignancies, or those unable to provide informed consent may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to earlier diagnosis and treatment of GBS and CIDP, improving patient outcomes.

How similar studies have performed: While the use of NMUS in diagnosing nerve disorders is emerging, this specific approach has not been extensively tested, making it a novel investigation.

Eligibility criteria

Inclusion Criteria:

1. Diagnosis of patient group:

   * GBS Patients: Diagnosed according to the criteria of the National Institute of Neurological Disorders and Stroke (NINDS) and the Brighton Collaboration (2011).
   * CIDP Patients: Diagnosed according to the criteria of the European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS).
2. Age: Participants aged 18 to 75 years.
3. Onset:

   * GBS Patients: Recent onset of GBS within the first 2 weeks of symptom onset.
   * CIDP Patients: Either relapsing or progressive course consistent with CIDP diagnosis.
4. Gender: Both male and female participants are eligible.
5. Participation: Willingness to participate in the study, including undergoing disease-related examinations and assessments.
6. Consent: Ability and willingness to provide informed consent

Exclusion Criteria:

1. Patients unable or unwilling to provide informed consent.
2. Patients with metabolic disorders or malignancies.
3. Patients with other causes of peripheral neuropathy.
4. Patients with other causes of acute flaccid paralysis.

Where this trial is running

Asyut

• Assiut University Hospitals — Asyut, Egypt (Recruiting)

Study contacts

• Study coordinator: Mohammed Gad Ibrahim, MB, BCh

Conditions Guillain Barré Syndrome; Chronic Inflammatory Demyelinating Polyradiculoneuropathy; Peripheral Nerve Disorder; Peripheral Nerves US; Peripheral Neuropathy; Peripheral nerve ultrasound; immune mediated nerve disorders; Guillain-Barré syndrome